.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Precision Medicine in Breast Cancer: Targeted Therapies and Biomarker-Guided Treatment Strategies

EP. 1: Dr Jhaveri on the Evolution of Treatment With ADCs in HER2-Expressing Breast Cancer

July 17th 2024

Komal Jhaveri, MD, FACP, discusses the evolution of antibody-drug conjugates for patients with HER2-positive, HER2-low or HER2-ultralow metastatic breast cancer.